CN101128461B - 作为VEGF-R2抑制剂的咪唑并[1,2-a]吡啶化合物 - Google Patents

作为VEGF-R2抑制剂的咪唑并[1,2-a]吡啶化合物 Download PDF

Info

Publication number
CN101128461B
CN101128461B CN2006800060044A CN200680006004A CN101128461B CN 101128461 B CN101128461 B CN 101128461B CN 2006800060044 A CN2006800060044 A CN 2006800060044A CN 200680006004 A CN200680006004 A CN 200680006004A CN 101128461 B CN101128461 B CN 101128461B
Authority
CN
China
Prior art keywords
pyridin
phenyl
imidazo
mmol
tert
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2006800060044A
Other languages
English (en)
Chinese (zh)
Other versions
CN101128461A (zh
Inventor
D·A·鲍尔达
T·P·伯克霍德尔
J·R·克莱顿
Y·郝
P·C·海特
J·R·亨利
J·M·诺贝洛克
D·曼德尔
J·A·麦克林恩
D·M·雷米克
M·E·莱帕拉
Z-Q·王
Y·Y·M·伊普
B·钟
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of CN101128461A publication Critical patent/CN101128461A/zh
Application granted granted Critical
Publication of CN101128461B publication Critical patent/CN101128461B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN2006800060044A 2005-02-24 2006-02-23 作为VEGF-R2抑制剂的咪唑并[1,2-a]吡啶化合物 Expired - Fee Related CN101128461B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US65598105P 2005-02-24 2005-02-24
US60/655,981 2005-02-24
PCT/US2006/006283 WO2006091671A1 (en) 2005-02-24 2006-02-23 Imidazo (1, 2-a) pyridine compounds as vegf-r2 inhibitors

Publications (2)

Publication Number Publication Date
CN101128461A CN101128461A (zh) 2008-02-20
CN101128461B true CN101128461B (zh) 2010-12-22

Family

ID=36587138

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2006800060044A Expired - Fee Related CN101128461B (zh) 2005-02-24 2006-02-23 作为VEGF-R2抑制剂的咪唑并[1,2-a]吡啶化合物

Country Status (33)

Country Link
US (1) US7666879B2 (https=)
EP (1) EP1904494B1 (https=)
JP (1) JP5055136B2 (https=)
KR (1) KR100904938B1 (https=)
CN (1) CN101128461B (https=)
AR (1) AR056186A1 (https=)
AT (1) ATE490254T1 (https=)
AU (1) AU2006216710B2 (https=)
BR (1) BRPI0609047A2 (https=)
CA (1) CA2599124C (https=)
CR (1) CR9331A (https=)
CY (1) CY1111154T1 (https=)
DE (1) DE602006018615D1 (https=)
DK (1) DK1904494T3 (https=)
DO (1) DOP2006000051A (https=)
EA (1) EA011691B1 (https=)
ES (1) ES2354716T3 (https=)
HR (1) HRP20100677T1 (https=)
IL (1) IL184717A (https=)
MA (1) MA29433B1 (https=)
MX (1) MX2007010326A (https=)
NO (1) NO20074666L (https=)
NZ (2) NZ584753A (https=)
PE (1) PE20061098A1 (https=)
PL (1) PL1904494T3 (https=)
PT (1) PT1904494E (https=)
RS (1) RS51590B (https=)
SI (1) SI1904494T1 (https=)
TN (1) TNSN07323A1 (https=)
TW (1) TW200640924A (https=)
UA (1) UA91535C2 (https=)
WO (1) WO2006091671A1 (https=)
ZA (1) ZA200707136B (https=)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8513276B2 (en) 2006-12-22 2013-08-20 Astex Therapeutics Limited Imidazo[1,2-a]pyridine compounds for use in treating cancer
US8131527B1 (en) 2006-12-22 2012-03-06 Astex Therapeutics Ltd. FGFR pharmacophore compounds
HRP20150642T1 (hr) * 2006-12-22 2015-08-14 Astex Therapeutics Limited BICIKLIÄŚKE HETEROCIKLIÄŚKE TVARI KAO INHIBITORI FGFR-a
US20110105602A2 (en) 2007-03-08 2011-05-05 Daria Mochly-Rosen Mitochondrial Aldehyde Dehydrogenase-2 Modulators and Methods of Use Thereof
GB0720038D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New compounds
GB0720041D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New Compounds
AR068877A1 (es) * 2007-10-17 2009-12-09 Novartis Ag Derivados heterociclicos de imidazol
GB0810902D0 (en) 2008-06-13 2008-07-23 Astex Therapeutics Ltd New compounds
US8354435B2 (en) 2008-09-08 2013-01-15 The Board Of Trustees Of The Leland Stanford Junior University Modulators of aldehyde dehydrogenase activity and methods of use thereof
CN102202669A (zh) 2008-10-28 2011-09-28 利兰·斯坦福青年大学托管委员会 醛脱氢酶调节剂及其使用方法
JO3265B1 (ar) 2008-12-09 2018-09-16 Novartis Ag مثبطات بيريديلوكسى اندولات vegf-r2 واستخدامها لعلاج المرض
US8278302B2 (en) 2009-04-08 2012-10-02 Boehringer Ingelheim International Gmbh Substituted piperidines as CCR3 antagonists
GB0906470D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
GB0906472D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
TW201124391A (en) 2009-10-20 2011-07-16 Lundbeck & Co As H 2-substituted-ethynylthiazole derivatives and uses of same
GB201009731D0 (en) 2010-06-10 2010-07-21 Pulmagen Therapeutics Inflamma Kinase inhibitors
UA109290C2 (uk) 2010-10-07 2015-08-10 Спільні кристали і солі інгібіторів ccr3
US10457659B2 (en) 2011-04-29 2019-10-29 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for increasing proliferation of adult salivary stem cells
US8680280B2 (en) * 2012-04-02 2014-03-25 Boehringer Ingelheim International Gmbh Process for the manufacturing of CRR inhibitors
US10213421B2 (en) 2012-04-04 2019-02-26 Alkahest, Inc. Pharmaceutical formulations comprising CCR3 antagonists
JP6430383B2 (ja) * 2012-09-28 2018-11-28 ヴァンダービルト ユニバーシティーＶａｎｄｅｒｂｉｌｔ Ｕｎｉｖｅｒｓｉｔｙ 選択的ｂｍｐ阻害剤としての縮合複素環化合物
KR101735975B1 (ko) * 2012-11-29 2017-05-15 에프. 호프만-라 로슈 아게 이미다조피리딘 유도체
WO2014160185A2 (en) 2013-03-14 2014-10-02 The Board Of Trustees Of The Leland Stanford Junior University Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof
CA2933811C (en) 2013-12-16 2021-02-09 Asana Biosciences, Llc P2x3 and/or p2x2/3 compounds and methods
CN103772308B (zh) * 2013-12-31 2015-11-18 北京颖泰嘉和生物科技股份有限公司 5-氨基-3-(1-乙基-1-甲基丙基)异噁唑中间体的制备方法和异噁草胺的制备方法
US9988371B2 (en) 2014-06-03 2018-06-05 The Arizona Board Of Regents On Behalf Of The University Of Arizona Benzimidazole analogues and related methods
US10065934B2 (en) 2014-07-17 2018-09-04 Sunshine Lake Pharma Co., Ltd. Substituted urea derivatives and pharmaceutical uses thereof
CN104163790B (zh) * 2014-08-19 2016-02-10 贵州威顿晶磷电子材料股份有限公司 一种2-氨基-4-甲基-5溴吡啶的制备工艺
US10829484B2 (en) 2015-07-28 2020-11-10 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
US10730842B2 (en) 2015-09-03 2020-08-04 Arizona Board Of Regents On Behalf Of The University Of Arizona Small molecule inhibitors of DYRK1A and uses thereof
ES2904615T3 (es) * 2016-03-16 2022-04-05 Plexxikon Inc Compuestos y métodos para la modulación de quinasas e indicaciones al respecto
US12528810B2 (en) 2018-03-01 2026-01-20 Arizona Board Of Regents On Behalf Of The University Of Arizona Small molecule inhibitors of DYRK/CLK and uses thereof
WO2019178383A1 (en) 2018-03-14 2019-09-19 Vanderbilt University Inhibition of bmp signaling, compounds, compositions and uses thereof
US10239885B1 (en) 2018-06-18 2019-03-26 Avista Pharma Solutions, Inc. Compound 1-[2-[4-(2-ethyl-6,8-dimethylimidazo[1,2-α]pyrazin-3-yl)phenyl]ethyl]-3-(p-tolylsulfonyl)urea as a prostaglandin EP4 receptor antagonist
SG11202106304RA (en) 2018-12-31 2021-07-29 Biomea Fusion Llc Irreversible inhibitors of menin-mll interaction
US11174263B2 (en) 2018-12-31 2021-11-16 Biomea Fusion, Inc. Inhibitors of menin-MLL interaction
BR112021013557A2 (pt) 2019-01-11 2021-09-21 Grünenthal GmbH Amidas de pirrolidina substituídas iii
CA3128024A1 (en) 2019-01-30 2020-08-06 Avista Pharma Solutions, Inc. Chemical compounds
MX2021009251A (es) 2019-01-30 2021-09-21 Avista Pharma Solutions Inc Proceso de sintesis y nuevos compuestos intermedios.
EP3904355B1 (en) * 2019-02-18 2024-11-20 Shenzhen TargetRx, Inc. Substituted fused aromatic ring derivative, composition and use thereof
CN114466847A (zh) * 2019-06-25 2022-05-10 西诺普塞疗法公司 用于治疗癌症的化合物
CN112778294A (zh) * 2021-01-07 2021-05-11 苏州安睿药业有限公司 5-氨基异噁唑衍生物及其在制备多激酶抑制剂中的应用
TW202320796A (zh) 2021-08-11 2023-06-01 美商拜歐米富士恩股份有限公司 用於糖尿病的menin-mll相互作用之共價抑制劑
US12018032B2 (en) 2021-08-20 2024-06-25 Biomea Fusion, Inc. Crystalline forms of N-[4-[4-(4-morpholinyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(r)-[(1-oxo-2-propen-1-yl)amino]-1-piperidinyl]methyl]-2-pyridinecarboxamide as an irreversible inhibitor of menin-MLL interaction
WO2024155710A1 (en) 2023-01-18 2024-07-25 Biomea Fusion, Inc. Crystalline forms of n-[4-[4-(4-morpholinyl)-7h-pyrrolo[2,3-d]pyrimidin-6- yl]phenyl]-4-[[3(r)-[(l-oxo-2-propen-l-yl)amino]-l-piperidinyl]methyl]-2-pyridinecarboxamide as a covalent inhibitor of menin-mll interaction
WO2025038525A1 (en) * 2023-08-11 2025-02-20 Bioventures, Llc Fms-like tyrosine kinase 3 (flt3) inhibitors for treating cell proliferative diseases or conditions

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003092595A2 (en) * 2002-05-02 2003-11-13 Merck & Co., Inc Tyrosine kinase inhibitors
WO2004052315A2 (en) * 2002-12-11 2004-06-24 Merck & Co., Inc. Tyrosine kinase inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2103097A (en) 1996-03-15 1997-10-10 Zeneca Limited Cinnoline derivatives and use as medicine
AU744939B2 (en) 1997-09-26 2002-03-07 Merck & Co., Inc. Novel angiogenesis inhibitors
CA2374737C (en) 1999-07-09 2008-02-12 Boehringer Ingelheim Pharmaceuticals, Inc. Novel process for synthesis of heteroaryl-substituted urea compounds
US6492529B1 (en) 2000-01-18 2002-12-10 Boehringer Ingelheim Pharmaceuticals, Inc. Bis pyrazole-1H-pyrazole intermediates and their synthesis
WO2003005999A2 (en) 2001-07-11 2003-01-23 Boehringer Ingelheim Pharmaceuticals, Inc. Methods of treating cytokine mediated diseases
JP2003313126A (ja) * 2002-04-23 2003-11-06 Sankyo Co Ltd イミダゾピリジン誘導体を有効成分とする医薬
AU2003298942A1 (en) * 2002-12-11 2004-06-30 Merck And Co., Inc. Tyrosine kinase inhibitors
EP1657242A4 (en) 2003-08-15 2008-10-29 Banyu Pharma Co Ltd imidazopyridine

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003092595A2 (en) * 2002-05-02 2003-11-13 Merck & Co., Inc Tyrosine kinase inhibitors
WO2004052315A2 (en) * 2002-12-11 2004-06-24 Merck & Co., Inc. Tyrosine kinase inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Zhicai Wu,et. al.Design and synthesis of 3,7-diarylimidazopyridinesasinhibitorsof the VEGF-receptor KDR.Bioorganic & Medicinal Chemistry Letters14 4.2004,14(4),909-912. *

Also Published As

Publication number Publication date
IL184717A (en) 2011-11-30
CR9331A (es) 2008-03-31
US20090227622A1 (en) 2009-09-10
TNSN07323A1 (en) 2008-12-31
AR056186A1 (es) 2007-09-26
HRP20100677T1 (hr) 2011-01-31
RS51590B (sr) 2011-08-31
PE20061098A1 (es) 2006-10-20
CY1111154T1 (el) 2015-06-11
AU2006216710A1 (en) 2006-08-31
DK1904494T3 (da) 2011-02-21
EP1904494B1 (en) 2010-12-01
US7666879B2 (en) 2010-02-23
TW200640924A (en) 2006-12-01
DOP2006000051A (es) 2006-08-31
NO20074666L (no) 2007-11-09
HK1118284A1 (en) 2009-02-06
EA011691B1 (ru) 2009-04-28
KR100904938B1 (ko) 2009-06-29
IL184717A0 (en) 2007-12-03
ES2354716T3 (es) 2011-03-17
AU2006216710B2 (en) 2011-08-11
KR20070099029A (ko) 2007-10-08
JP2008531574A (ja) 2008-08-14
PT1904494E (pt) 2010-12-23
SI1904494T1 (sl) 2011-02-28
PL1904494T3 (pl) 2011-04-29
UA91535C2 (en) 2010-08-10
DE602006018615D1 (de) 2011-01-13
CA2599124C (en) 2013-08-06
CN101128461A (zh) 2008-02-20
ZA200707136B (en) 2008-11-26
BRPI0609047A2 (pt) 2010-11-16
NZ584753A (en) 2011-06-30
WO2006091671A1 (en) 2006-08-31
JP5055136B2 (ja) 2012-10-24
EA200701802A1 (ru) 2008-02-28
ATE490254T1 (de) 2010-12-15
EP1904494A1 (en) 2008-04-02
MX2007010326A (es) 2007-10-16
MA29433B1 (fr) 2008-05-02
CA2599124A1 (en) 2006-08-31
NZ560402A (en) 2010-06-25

Similar Documents

Publication Publication Date Title
CN101128461B (zh) 作为VEGF-R2抑制剂的咪唑并[1,2-a]吡啶化合物
EP2114941B1 (en) Bicyclic heterocyclic compounds as fgfr inhibitors
CN101553233B (zh) 用于治疗骨髓增生性疾病和其他增生性疾病的激酶抑制剂
CN102137859B (zh) 作为受体酪氨酸激酶的抑制剂的咪唑并吡啶衍生物
CN105683182A (zh) 联芳基乙酰胺化合物及其使用方法
CN101835752A (zh) 用于治疗癌症和银屑病的杂环酰胺
CN110114343B (zh) 吡唑并嘧啶化合物及其使用方法
CN101932580A (zh) 咪唑并吡啶激酶抑制剂
CN101005843A (zh) 吡咯并三嗪激酶抑制剂
HK1118284B (en) Imidazo[1,2-a]pyridine compounds as vegf-r2 inhibitors
HK1139036B (en) Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
HK40011970B (en) Pyrazolopyrimidine compounds and methods of use thereof
TW200836725A (en) New compounds

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20101222

Termination date: 20150223

EXPY Termination of patent right or utility model